Items tagged with Scientific research
Astellas and TB Alliance enter into a new collaborative research agreement to identify lead compounds for the treatment of TB (post)
TOKYO and NEW YORK (March 31, 2021) — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and TB Alliance (President and CEO: Mel Spigelman, M.D.), a non-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB) today announced that they have entered into a new collaborative research (“Hit-to-Lead PJ”) agreement to identify lead compounds for the treatment of TB.
New inhibitors may offer novel approach to treating deadly TB (post)
WEST LAFAYETTE, Ind. – Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
The TB pathogen releases its toxin by a novel protein transport system (post)
Six years ago, Michael Niederweis, Ph.D., described the first toxin ever found for the deadly pathogen Mycobacterium tuberculosis. This toxin, tuberculosis necrotizing toxin, or TNT, became the founding member of a novel class of previously unrecognized toxins present in more than 600 bacterial and fungal species, as determined by protein sequence similarity. The toxin is released as M. tuberculosis bacteria survive and grow inside their human macrophage host, killing the macrophage and allowing the escape and spread of the bacteria.
New study explains Mycobacterium tuberculosis high resistance to drugs and immunity (post)
A consortium of researchers from Russia, Belarus, Japan, Germany and France led by a Skoltech scientist have uncovered the way in which Mycobacterium tuberculosis survives in iron-deficient conditions by utilizing rubredoxin B, a protein from a rubredoxin family that play an important role in adaptation to changing environmental conditions. The new study is part of an effort to study the role of M. tuberculosis enzymes in developing resistance to the human immune system and medication. The paper was published in the journal Bioorganic Chemistry.
Starving TB of sugars may be a new way to fight it (post)
- Tuberculosis is one of the leading causes of death from a single infectious agent in the world, but the nutrients that the pathogen uses to survive in the body is poorly understood
- The bacteria that cause tuberculosis need a sugar called trehalose to survive and cause infection
- The molecular basis of how Mycobacterium tuberculosis uses and transports trehalose has been discovered by researchers from the University of Warwick
- This ignites new opportunities to develop new drugs and diagnostics targeted against TB
New research shows how immune response to TB differs in babies (post)
The immune response to tuberculosis (TB) differs in adults and newborn babies due to the way immune cells use energy to kick into gear in a bid to kill the bacteria. This fresh discovery – just published in leading journal, Frontiers in Immunology – offers hope for improving treatments for what remains a deadly disease.
BioVersys receives €20 million in EU financing to support development of new antibiotics (post)
-- European Investment Bank and BioVersys sign a financing agreement of up to €20 million to facilitate the development of new treatments against life-threatening resistant bacterial infections.
-- The venture debt loan is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the European Union’s research and innovation programme for 2014-2020.
-- BioVersys has a rich pipeline of drugs in clinical development for the treatment of tuberculosis and hospital-acquired infections, like ventilator-associated pneumonia, seen most recently in COVID-19 patients in intensive care. The company has additional preclinical assets and follow-on programmes all focusing on different unmet medical needs in antimicrobial resistance.
Disrupted movement makes macrophages more lethal to TB bacteria (post)
Macrophages – the front line of our immune system – protect us from infections. But in the case of the tuberculosis bacteria, this often goes wrong. The group of Annemarie Meijer from the Leiden Institute of Biology has now discovered that macrophages in zebrafish are better able to eliminate tuberculosis bacteria if they lack a certain receptor. The research, published in the journal Cell Reports, may contribute to new treatment strategies for tuberculosis.
Valo Therapeutics acquires University of Helsinki’s PeptiBAC cancer and infectious disease vaccination technology (post)
Helsinki, Finland, 19 April 2021: Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights for the proprietary ‘PeptiBAC’ technology from the University of Helsinki, Finland.
TB immune response discovery could significantly reduce disease harm (post)
A pioneering study by UCL scientists has discovered the presence of a harmful inflammatory protein in patients with symptomatic tuberculosis (TB).
Page 54 of 74 · Total posts: 0
←First 53 54 55 Last→